Key Drivers
- Strong Liquidity
- Persistent Losses
- Equity Dilution
AIAI Summary
IDYA is transitioning from a clinical-stage biotech to a potential commercial oncology franchise, with darovasertib's 2026 NDA as the decisive catalyst; investors should prioritize approval, label breadth, and rare-disease launch execution over its strong cash runway, since a setback would materially impair a valuation still dominated by this lead asset.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •Equity Dilution
IDYA has exceptional liquidity and minimal debt, but persistent losses, heavy cash burn, dilution risk, and a demanding valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Weak near-term trend
- •Key support test
- •Resistance overhead
IDYA remains weak over the last month, with support at $37.45–$37.60 needing to hold for a rebound above $38.85, while failure risks further downside.
Declined from $42.48 in late
Sentiment & News
Key News Insights:
- •Phase 3 progress
- •Darovasertib expansion
- •IDE849 momentum
IDEAYA's oncology pipeline is advancing toward pivotal trials, led by IDE849 in small-cell lung cancer and darovasertib in adjuvant uveal melanoma.
The updates strengthen IDEAYA's clinical catalysts and could support investor interest as pivotal trial milestones approach
Similar Companies in Healthcare
Other companies in the same sector with AI ratings